Understanding how lung cancer affects COVID-19 vulnerability
Official title: Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
Funded at Icahn School of Medicine at Mount Sinai · NIH-10688370 · Data updated 2026-11-12
This study is looking at how lung cancer affects patients' ability to fight off COVID-19 and how well vaccines work for them, so we can find better ways to keep lung cancer patients safe from the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 30, 2020 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $2,044,217 |
| NIH project number | 4U54CA260560-02 |
| Project ID | NIH-10688370 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with lung cancer who may be at increased risk for severe COVID-19.
✕Less likely to help
Patients without lung cancer or those who are not at risk for severe COVID-19 may not benefit from this research.
What this research studies
This research investigates why lung cancer patients are more vulnerable to severe outcomes from COVID-19 by analyzing their antibody responses to the virus. It compares the immune responses of lung cancer patients to those without lung cancer, focusing on how well their bodies can fight off the virus and the effectiveness of vaccines. The study will also examine how different lung cancer characteristics and treatments might influence these immune responses. By understanding these factors, the research aims to develop better protection strategies for lung cancer patients against COVID-19.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies and treatments specifically tailored for lung cancer patients to protect them from severe COVID-19 outcomes.
How similar studies have gone: Other research has shown that understanding immune responses in cancer patients can lead to significant advancements in treatment and protection strategies, indicating a promising approach in this area.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Hirsch, Fred R — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hirsch, Fred R
Related research
Other NIH-funded projects on the same topics.
-
How lung cancer affects immune responses to COVID-19
This study is looking at how people with lung cancer react to COVID-19 infections and vaccines, checking how well their immune systems work and what that means for their health over time.
-
Understanding how lung cancer affects COVID-19 vulnerability through antibody analysis
This study is looking at how lung cancer affects the way patients respond to COVID-19 and vaccines, so we can find better ways to protect them during the pandemic.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Alzheimer’s-related dementia after COVID-19: how SARS-CoV-2 affects the brain and potential drug repurposing
This research looks at how COVID-19 may contribute to dementia by studying brain inflammation, blood vessel injury, and virus-host interactions, with the goal of finding existing drugs that could help.
-
IL-22’s role in SARS-CoV-2 infection and tissue protection
A short study to understand how the cytokine IL-22 might help protect tissues during and after COVID-19 infection, especially in people with complications related to acute graft-versus-host disease.
-
Maternal SARS-CoV-2 infection and its effects on placenta and child development
This grant studies how COVID-19 infection during pregnancy might change the placenta and influence a child’s brain development, especially in kids who may be at higher genetic risk for ADHD/ASD.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.